North Carolina is a leading place for biotech, and a big part of that success comes from GlaxoSmithKline (GSK). This global ...
Dr. Ernest Mario, the founding chair of the Duke University Health System Board of Directors and a leader in the ...
In 2023, the market is anticipated to be valued at USD 26.64 Billion, marking a significant starting point for a decade-long ...
The Industry is on the brink of a substantial surge, with the market size expected to reach USD 100 Million in 2023 and ...
SBI Securities has recommended buying shares of Coal India, Macrotech Developers, Bharti Hexacom, Nippon Life India, Escorts ...
In patients with moderate to severe Crohn’s disease, guselkumab showed similar efficacy in both biologic-naive and ...
A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...
Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...
In patients with uncomplicated UTI, the presence of positive vs negative ESBL uropathogens differed by symptom severity, race, and age plus recurrent UTI history.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback